Abstract
Beta adrenergic receptors are very important in respiratory medicine. Traditionally, the stimulation of beta adrenergic receptors by beta2-agonists is commonly used for giving bronchodilation in chronic airflow obstruction However; the wide distribution of these receptors in cells and tissues other than airway smooth muscle suggests that beta agonists should offer other beneficial effects in respiratory disease. Recent studies have shown the importance of these receptors in the modulation of endocrine and immune system that affect respiratory function and may decrease therapy effectiveness in asthma and chronic obstructive pulmonary disease. New patented compound and uses have provided new insights in future therapeutics of respiratory diseases in which genetic, endocrine and immune response should be considered.
Keywords: Adrenergic receptor agonists, lymphocytes, macrophages, asthma, β2 adrenergic receptor, COPD, genetic polymorphism, immune response, neutrophils, LABA
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Title: Role of Beta2 Agonists in Respiratory Medicine with Particular Attention to Novel Patents and Effects on Endocrine System and Immune Response
Volume: 5 Issue: 3
Author(s): Nancy E. Larocca, Dolores Moreno, Jenny V. Garmendia and Juan B. De Sanctis
Affiliation:
Keywords: Adrenergic receptor agonists, lymphocytes, macrophages, asthma, β2 adrenergic receptor, COPD, genetic polymorphism, immune response, neutrophils, LABA
Abstract: Beta adrenergic receptors are very important in respiratory medicine. Traditionally, the stimulation of beta adrenergic receptors by beta2-agonists is commonly used for giving bronchodilation in chronic airflow obstruction However; the wide distribution of these receptors in cells and tissues other than airway smooth muscle suggests that beta agonists should offer other beneficial effects in respiratory disease. Recent studies have shown the importance of these receptors in the modulation of endocrine and immune system that affect respiratory function and may decrease therapy effectiveness in asthma and chronic obstructive pulmonary disease. New patented compound and uses have provided new insights in future therapeutics of respiratory diseases in which genetic, endocrine and immune response should be considered.
Export Options
About this article
Cite this article as:
E. Larocca Nancy, Moreno Dolores, V. Garmendia Jenny and B. De Sanctis Juan, Role of Beta2 Agonists in Respiratory Medicine with Particular Attention to Novel Patents and Effects on Endocrine System and Immune Response, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2011; 5 (3) . https://dx.doi.org/10.2174/187221411797265908
DOI https://dx.doi.org/10.2174/187221411797265908 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Interleukin-10
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammation, Allergy and Asthma, Complex Immune Origin Diseases: Mechanisms and Therapeutic Agents
Recent Patents on Inflammation & Allergy Drug Discovery Plant Coumestans: Recent Advances and Future Perspectives in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Quantitative Structure Activity Relationship (QSAR) Analysis of Substituted 4-Oxothiazolidines and 5-Arylidines as Lipoxygenase Inhibitors
Mini-Reviews in Medicinal Chemistry Heparins with Reduced Anti-Coagulant Activity Reduce Myocardial Reperfusion Injury
Recent Patents on Cardiovascular Drug Discovery Arylsulphones: A Promising Class of Non-Nucleoside Antiviral Agents
Current Medicinal Chemistry - Anti-Infective Agents Expression Levels of MicroRNA-125b in Serum Exosomes of Patients with Asthma of Different Severity and its Diagnostic Significance
Current Drug Metabolism Prevalence, Presentation and Outcome of Secondary Bloodstream Infections among COVID-19 Patients
Infectious Disorders - Drug Targets ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far
Current Alzheimer Research Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry IL-22 Produced by T helper Cell 22 as a New player in the Pathogenesis of Immune Thrombocytopenia
Endocrine, Metabolic & Immune Disorders - Drug Targets Cytokine Polymorphisms in Chronic Inflammatory Diseases with Reference to Occupational Diseases
Current Molecular Medicine Oxidative Stress and Gene Transcription in Asthma and Chronic Obstructive Pulmonary Disease: Antioxidant Therapeutic Targets
Current Drug Targets - Inflammation & Allergy Xenobiotic-Metabolizing Enzymes in Human Lung
Current Drug Metabolism Therapeutic Potential of Alkaloids as Anti-Bacterial Agents: Drugs of Future
Current Bioactive Compounds Identifying Patterns in Signs and Symptoms Preceding the Clinical Diagnosis of Alzheimer’s Disease: Retrospective Medical Record Review Study and a Nested Case-control Design
Current Alzheimer Research Safety of Inhaled Fluticasone Propionate Therapy for Pediatric Asthma - A Systematic Review
Current Drug Safety